When it strikes, the patient has nowhere else to turn.
When a fungal infection takes hold inside the eye, it moves quickly toward blindness, and the drugs available to stop it have long been few. A new preclinical study now places two echinocandin compounds — rezafungin and anidulafungin — alongside the established treatments, suggesting that medicine's narrow corridor of options may be widening. The work, conducted in laboratory cultures and rabbit models, does not yet constitute a cure, but it marks the kind of careful threshold-crossing that eventually changes what physicians can offer their patients.
- Aspergillus fumigatus endophthalmitis is rare but catastrophic — capable of destroying a patient's vision within days if the right treatment is not found quickly.
- The existing standard drugs, liposomal amphotericin B and voriconazole, carry limitations in tolerability and mechanism, leaving clinicians with little room to maneuver when those options fail.
- In laboratory tests, rezafungin and anidulafungin dismantled fungal biofilms, visibly damaged cell walls and membranes, and suppressed key inflammatory signals — all at low, potentially therapeutic concentrations.
- In infected rabbit eyes, both echinocandins matched the performance of the established treatments, reducing fungal burden, intraocular inflammation, and inflammatory markers in the eye's fluid.
- The findings are preclinical and the road to human trials remains long, but the study clears a meaningful scientific threshold — transforming these drugs from theoretical candidates into grounded possibilities.
A fungal infection inside the eye is a medical emergency. Aspergillus fumigatus endophthalmitis moves fast, and without effective treatment, it can permanently blind a patient within days. For years, clinicians have relied on two drugs — liposomal amphotericin B and voriconazole — injected directly into the eye's interior. A new study suggests that two additional compounds may belong in that same conversation.
Researchers tested rezafungin and anidulafungin, both echinocandins, first in laboratory conditions and then in living rabbits. In the lab, the drugs proved potent at low concentrations, disrupted fungal biofilm formation, and caused visible structural damage to fungal cell walls and membranes under multiple microscopy techniques. They also suppressed TNF-α and IL-1β — the inflammatory molecules that amplify tissue damage during infection.
In the animal phase, rabbit eyes were infected with Aspergillus fumigatus and then treated with one of five agents, including the two echinocandins, the two standard drugs, or a saline control. Both rezafungin and anidulafungin reduced fungal burden, lowered intraocular inflammation scores, and cut TNF-α levels in the aqueous humor — results that matched those of the established treatments. Tissue examination confirmed less damage in treated eyes compared to controls.
Aspergillus endophthalmitis is uncommon enough that many ophthalmologists encounter it rarely, but when it strikes, the consequences are total. The significance of these findings lies not in solving a widespread crisis but in expanding the options available when standard drugs are not tolerated or when resistance emerges. Echinocandins also attack the fungal cell wall through a different mechanism than amphotericin B or azoles, which could prove decisive in cases where older treatments fail.
These results are preclinical — proof of concept rather than proof of clinical safety or efficacy. The path to human trials is long. But the study clears a threshold, giving researchers and clinicians reasonable scientific grounds to move forward. For now, the work occupies that productive space between laboratory possibility and clinical reality.
A fungal infection of the eye—endophthalmitis caused by Aspergillus fumigatus—is a medical emergency. Left untreated, it destroys vision. The standard arsenal of drugs that fight it has been limited: liposomal amphotericin B and voriconazole have long been the go-to treatments, injected directly into the eye's interior chamber. Now, a new study suggests two alternatives might work just as well.
Researchers tested rezafungin and anidulafungin, both members of a drug class called echinocandins, against the fungus in laboratory conditions and then in living rabbits. The question was straightforward: could these drugs do what the established treatments do, and could they do it without the side effects that sometimes accompany the older options?
In the lab, the two echinocandins proved potent. They worked at low concentrations—meaning smaller doses might be effective. They stopped the fungus from forming biofilms, those protective communities of cells that make infections harder to treat. Under microscopes—confocal, scanning electron, transmission electron—the drugs visibly damaged the fungal cell wall and membrane, the structures that hold the organism together. The researchers also measured inflammatory markers, the chemical signals that the body's immune system releases during infection. Both drugs suppressed TNF-α and IL-1β, molecules that drive inflammation, in cultured macrophages.
Then came the animal work. The team infected rabbit eyes with Aspergillus fumigatus, waited 24 hours, and then injected one of five treatments directly into the eye: liposomal amphotericin B, voriconazole, rezafungin, anidulafungin, or saline as a control. Over the following period, they tracked clinical inflammation scores—how red and swollen the eye became—and measured the actual fungal load inside the eye. They also checked the aqueous humor, the clear fluid that fills the front chamber, for TNF-α levels. Finally, they examined tissue samples under the microscope to see what damage the infection and treatment had caused.
The results were striking in their consistency. Rezafungin and anidulafungin reduced intraocular inflammation, cut the fungal burden, and lowered TNF-α in the aqueous humor. Their performance matched that of liposomal amphotericin B and voriconazole—the drugs already proven in clinical use. The histopathology told the same story: eyes treated with either echinocandin showed less tissue damage than untreated controls.
What makes this finding significant is not that it solves a crisis—Aspergillus endophthalmitis is rare enough that most ophthalmologists may see only a handful of cases in a career. But when it does occur, the stakes are total. The infection can blind a patient within days. Having more weapons in the arsenal matters. Rezafungin and anidulafungin offer the possibility of alternatives if a patient cannot tolerate the standard drugs, or if resistance emerges. They also represent a different mechanism of action: echinocandins attack the fungal cell wall in a way that amphotericin B and azoles do not, which could matter in cases where the older drugs fail.
The path from rabbit model to human clinic is long. These results are preclinical—proof of concept, not proof of safety or efficacy in patients. But they clear a threshold. They suggest that when researchers and clinicians eventually design human trials, they will have reasonable grounds to proceed. For now, the finding sits in that productive space where laboratory science meets clinical possibility: not yet a treatment, but no longer merely theoretical.
La Conversación del Hearth Otra perspectiva de la historia
Why does a fungal eye infection matter enough to study in rabbits? How common is this?
It's rare, but when it happens, it's catastrophic. Aspergillus fumigatus endophthalmitis can blind someone in days. Most ophthalmologists see only a handful of cases in their entire career. But that rarity is exactly why we need options—when it does strike, the patient has nowhere else to turn.
So the current drugs work. Why do we need new ones?
They do work, but they're not perfect. Some patients can't tolerate them. Some infections might develop resistance. And having a different mechanism—a different way of attacking the fungus—gives you a backup plan when the first line fails.
What did the echinocandins actually do to the fungus?
They damaged the cell wall and membrane. Under electron microscopes, you could see the structural breakdown. They also stopped the fungus from forming biofilms, those protective communities that make infections harder to treat. And they quieted the inflammatory response—the body's own immune reaction that causes much of the damage.
How close are we to using these in patients?
Not yet. This is preclinical work—rabbits, not humans. But it clears the threshold. It gives researchers and clinicians grounds to design human trials. Right now, it's proof that the idea works. The next step is proving it's safe and effective in people.
What happens if these drugs fail in a human trial?
Then we're back where we started. But if they succeed, we've expanded the toolkit. For a disease this rare and this serious, that matters enormously.